Table 2.
Patient clinical and demographic characteristics at time of survey
| All* N=265 |
Form 1¶ N=91 |
Form 2¶ N=85 |
Form 3 N=90 |
|
|---|---|---|---|---|
| Age in years, M (IQR) | 12 (9, 15) | 11 (9, 14) | 13 (10, 16) | 12 (9, 15) |
| Sex: Female, N (%) | 185 (69.8%) | 66 (72.5%) | 57 (67.1%) | 63 (70.0%) |
| Race, N (%) | ||||
| White | 225 (84.9%) | 77 (84.6%) | 73 (85.9%) | 76 (84.4%) |
| Black/African American | 18 (6.8%) | 7 (7.7%) | 4 (4.7%) | 7 (7.8%) |
| Asian | 3 (1.1%) | 2 (2.2%) | 1 (1.2%) | 0 (0.0%) |
| Other | 16 (6.0%) | 4 (4.4%) | 6 (7.1%) | 6 (6.7%) |
| More than one race | 3 (1.1%) | 1 (1.1%) | 1 (1.2%) | 1 (1.1%) |
| JIA subtype, N (%) | ||||
| Enthesitis-related arthritis | 58 (21.9%) | 16 (17.6%) | 24 (28.2%) | 18 (20.0%) |
| Oligoarticular arthritis | 85 (32.1%) | 27 (29.7%) | 27 (31.8%) | 31 (34.4%) |
| Polyarticular rheumatoid factor − | 57 (21.5%) | 22 (24.2%) | 17 (20.0%) | 19 (21.1%) |
| Polyarticular rheumatoid factor + | 4 (1.5%) | 0 (0.0%) | 1 (1.2%) | 3 (3.3%) |
| Psoriatic arthritis | 24 (9.1%) | 9 (9.9%) | 7 (8.2%) | 8 (8.9%) |
| Systemic | 12 (4.5%) | 5 (5.5%) | 2 (2.4%) | 5 (5.6%) |
| Undifferentiated | 25 (9.4%) | 12 (13.2%) | 7 (8.2%) | 6 (6.7%) |
| JADAS3 score, M (IQR) | 1 (0, 4) | 1 (0, 4) | 1 (0, 4) | 1 (0, 4) |
| JADAS3 disease state§, N (%) | ||||
| Inactive Disease | 130 (52.6%) | 43 (51.2%) | 43 (54.4%) | 45 (52.9%) |
| Active Disease | 117 (47.4%) | 41 (48.8%) | 36 (45.6%) | 40 (47.1%) |
| Survey Responses¶, N (%) | N=452 | 154 (34.1%) | 145 (32.1%) | 153 (33.8%) |
| Patient-reported | 229 (50.7%) | 77 (50.0%) | 74 (51.0%) | 78 (51.0%) |
| Parent-reported | 223 (49.3%) | 77 (50.0%) | 71 (49.0%) | 75 (49.0%) |
| Patient-parent dyads | 185 | 63 | 59 | 63 |
Abbreviations: JADAS 3: Juvenile Arthritis Disease Activity Score 3; JIA: Juvenile Idiopathic Arthritis; M (IQR): Median (Interquartile range).
All is a reference to all unique patients in the study (excludes repeated patient information from dyads and also the repeated information from the patient who completed 2 forms);
One patient completed two forms (forms 1 and 2).
JADAS3 disease activity states were consolidated from 4 categories (inactive, low, moderate, and high disease activity) to 2 categories by combining low, moderate and high disease activity into a new category called “active disease”.
Form 1=Anger, Anxiety, Depressive Symptoms, and Peer Relationships; Form 2=Pain Interference; Form 3=Fatigue, Mobility, Upper Extremity Function. No significant differences (p<0.05) in participant characteristics existed between Form 1, Form 2, and Form 3 as tested by Kruskal-Wallis or chi-squared test, as appropriate.